Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

LTRN Lantern Pharma Inc

5,07

-0,23 (-4,34%)

07 Fev 2025 - Fechado

Atrasado em 15 minutos

Annual Report to Security Holders (ars)

This regulatory filing also includes additional resources:
formars.pdf

Lantern Pharma (NASDAQ:LTRN)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Click aqui para mais gráficos Lantern Pharma.

Lantern Pharma (NASDAQ:LTRN)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025

Click aqui para mais gráficos Lantern Pharma.

Notícias Lantern Pharma Inc.

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
Segunda, 27 de Janeiro de 2025 (2 semanas atrás) • Business Wire

Form 8-K - Current report
Sexta, 10 de Janeiro de 2025 (4 semanas atrás) • Edgar (US Regulatory)

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Segunda, 9 de Dezembro de 2024 (2 meses atrás) • Business Wire

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Terça, 3 de Dezembro de 2024 (2 meses atrás) • Business Wire

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Terça, 26 de Novembro de 2024 (2 meses atrás) • Business Wire

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Terça, 19 de Novembro de 2024 (3 meses atrás) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Quinta, 7 de Novembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Quinta, 7 de Novembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
Quinta, 7 de Novembro de 2024 (3 meses atrás) • Business Wire

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
Terça, 5 de Novembro de 2024 (3 meses atrás) • Business Wire

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
Quinta, 31 de Outubro de 2024 (3 meses atrás) • Business Wire

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
Quarta, 23 de Outubro de 2024 (4 meses atrás) • Business Wire

Mais Notícias de Lantern Pharma Inc.

Northrop Grumman

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições